

FORM PTO-1449/A and B (modified PTO/SB/08)

APPLICATION NO.: 10/735,592

ATTY. DOCKET NO.: C1037.70038US01

FILING DATE: December 11, 2003

CONFIRMATION NO.: 2533

APPLICANT: Arthur M. Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet

1 of 2

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****U.S. PATENT DOCUMENTS**

Examiner's Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,806,463		Goodchild et al.	02-21-1989
		5,004,810		Draper	04-02-1991
		5,166,195		Ecker	11-24-1992
		5,194,428		Agrawal et al.	03-16-1993
		5,264,423		Cohen et al.	11-23-1993
		5,276,019		Cohen et al.	01-04-1994
		5,696,248		Peyman et al.	12-09-1997
		6,506,386	B1	Friede et al.	01-14-2003
		6,749,856	B1	Berzofsky et al.	06-15-2004
		6,852,705	B2	Audonnet et al.	02-08-2005
		7,354,909	B2	Klinman et al.	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		7,488,490	B2	Davis et al.	02-10-2009
		7,517,861	B2	Krieg et al.	04-14-2009
		7,524,828	B2	Krieg et al.	04-28-2009
		7,534,772	B2	Weiner et al.	05-19-2009
		2003-0176389	A1	Raz et al.	09-18-2003
		2003-0225016	A1	Fearon et al.	12-04-2003
		2003-0232443	A1	Bennett et al.	12-18-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2005-0019340	A1	Garcon et al.	01-27-2005
		2005-0238660	A1	Babiuk et al.	10-27-2005
		2007-0202575	A1	Klinman et al.	08-03-2007
		2007-0258994	A1	Van Nest et al.	11-08-2007
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0152662	A1	Agrawal et al.	06-26-2008
		2008-0226649	A1	Schetter et al.	09-18-2008
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009
		2009-0155307	A1	Davis et al.	06-18-2009

EXAMINER:

/N. M. Minnifield/ (10/14/2009)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.

1708824.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Arthur M. Krieg et al.	
Sheet	2	of	2	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	1 187 629	A2	Smithkline Beecham Biologicals, S.A.	10-26-2000	
		EP	1 550 458	A1	Vectron Therapeutics AG	07-06-2005	
		WO	97/30728	A1	Morein et al.	08-28-1997	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	
		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		FATHI et al., Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. Nucleic Acids Res. 1994 Dec 11;22(24):5416-24.	
		JIANG et al., Synthetic vaccines: the role of adjuvants in immune targeting. Curr Med Chem. 2003 Aug;10(15):1423-39.	
		JOSEPH et al., Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine. 2002 Sep 10;20(27-28):3342-54.	
		LYER et al., Modified oligonucleotides—synthesis, properties and applications. Curr Opin Mol Ther. 1999 Jun;1(3):344-58. Review.	
		MARSHALL et al., Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003 Jun;73(6):781-92.	
		SCHEULE, The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):119-34.	
		VERTHELYI et al., CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol. 2002 Feb 15;168(4):1659-63.	
		VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antiv Ther. 2002;7:L115.	
		VOLLMER, CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol. 2006 May-Aug;25(3-4):125-34. Abstract.	
		WILSON et al., Complex roles of CpG in liposomal delivery of DNA and oligonucleotides. Biosci Rep. 2002 Apr;22(2):309-22. Review.	
		YU et al., 'Immunomers'—novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002 Oct 15;30(20):4460-9.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /N. M. Minnifield/ (10/14/2009)	DATE CONSIDERED:
--	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.